Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...
As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...
The Families for Friedreich’s Ataxia Foundation is grateful for the incredible support from Chelsea and the surrounding ...
EatingWell on MSN6d
7 Habits That Could Lower Your Dementia Risk, According to a New StudyThey may lower your risk of other neurodegenerative diseases, too. Reviewed by Dietitian Annie Nguyen, M.A., RD A new study ...
Title: Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne ...
Cerebellar rhythm loss due to climbing fiber regression is a shared pathophysiology of motor deficits across cerebellar ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...
Design has initiated dosing in a Phase 1 clinical trial in healthy volunteers in Australia to evaluate the safety and ...
PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback